EYLEA(R) (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial

Expect U.S. regulatory submission for diabetic retinopathy later this year TARRYTOWN, N.Y., March 19, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 PANORAMA trial evalu... Biopharmaceuticals, Ophthalmology Regeneron Pharmaceuticals, EYLEA, aflibercept, macular degeneration
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news